ZIANA® is developed by Actavis Mid-Atlantic LLC.

What development phase is ZIANA® in?

ZIANA® is FDA-approved (marketed).

What are the side effects of ZIANA®?

Common side effects include Erythema, Scaling, Itching, Nasopharyngitis, Burning, Stinging.

Last reviewed 2026-04-20 · How we verify

ZIANA®

Actavis Mid-Atlantic LLC · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	ZIANA®
Sponsor	Actavis Mid-Atlantic LLC
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Erythema
Scaling
Itching
Nasopharyngitis
Burning
Stinging
Pharyngolaryngeal pain
Dry skin
Cough
Sinusitis
Gastrointestinal symptoms

Key clinical trials

Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ZIANA® CI brief — competitive landscape report
ZIANA® updates RSS · CI watch RSS
Actavis Mid-Atlantic LLC portfolio CI